Abstract 48P
Background
Oxyphilic adenocarcinoma, or Hürthle cell carcinoma (HCC), a rare subtype of thyroid cancer, accounts for 3-5% of all thyroid cancers. HCC is more prevalent in females and typically presents in older individuals. HCC tends to present with larger tumors and higher disease stages compared to other differentiated thyroid cancers. We aim to analyse the survival outcomes of patients with HCC over the past 20 years in US.
Methods
Data was collected from Surveillance, Epidemiology, and End Results (SEER) Research plus data (from 2000 to 2021). Using the ICD code 8290/3, we extracted patients diagnosed with oxyphilic adenocarcinoma of thyroid. We included patients older than 20 years at the time of diagnosis. Analysis was stratified based on age, sex, race, stage, median household income and residency. Survival analysis was done with Graphpad Prism software.
Results
5119 patients with oxyphilic adenocarcinoma of thyroid were identified. 68.47% were female, and 31.53% were male. The cohort contained 72.63% caucasian, 11.94% hispanic, 7.99% black, 6.17% Asian or pacific islander, and 0.45% American/Alaska native. 88.14% of patients resided in metropolitan areas, and 11.7% in non metropolitan areas. 68.12% had localized disease, 9.79% regional, whereas 4.10% had distant disease. The 5-, 10- and 20-year overall survival rates were 87.947%, 77.64% and 58.493% respectively. Median overall survival (mOS) was worse in males (232 months, p<0.0001), compared to females (hazard ratio 1.644, 95% CI 1.447 to 1.867). When comparing survival outcomes by race, there was a significant difference in 10- and 20- year survival rates - 82.127% and 65.629% in hispanics, 77.506% and 57.058% in blacks and 76.35% and 57.211% in caucasians respectively (p<0.0009). mOS was lower in patients with median household income < $55,000, compared to those with higher income (p<0.0001). HCC patients living in non-metropolitan counties had less favourable survival with mOS of 203 months, p<0.0001 (HR 1.625, 95% CI 1.352 to 1.954).
Conclusions
Survival outcomes are worse in blacks, low income households, residents of non metropolitan areas and in males with HCC. Further studies need to explore such disparities in survival outcomes and address factors affecting survival in these groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.